Lumacaftor/ Ivacaftor improves exercise tolerance in patients with Cystic Fibrosis and severe airflow obstruction

Exercise performance and quality of life in children with cystic fibrosis and mildly impaired lung function: relation with antibiotic treatments and hospitalization

(2017) Kristof Vandekerckhove et al.   EUROPEAN JOURNAL OF PEDIATRICS

2017 ERS/ATS standards for single-breath carbon monoxide uptake in the lung

(2017) Brian L. Graham et al.   EUROPEAN RESPIRATORY JOURNAL

Immediate effects of lumacaftor/ivacaftor administration on lung function in patients with severe cystic fibrosis lung disease

(2017) Natalia Popowicz et al.   Journal of Cystic Fibrosis

The quantitative link of lung clearance index to bronchial segments affected by bronchiectasis

(2017) Sylvia Verbanck et al.   THORAX

Minimal clinically important difference for change in 6-minute walk test distance of adults with pathology: a systematic review

(2016) Richard W. Bohannon et al.   JOURNAL OF EVALUATION IN CLINICAL PRACTICE

Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis

(2016) J Stuart Elborn et al.   Lancet Respiratory Medicine

Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR

(2015)   NEW ENGLAND JOURNAL OF MEDICINE

Association between peripheral airway function and neutrophilic inflammation in asthma

(2015) Claude S. Farah et al.   RESPIROLOGY

An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease

(2014) Anne E. Holland et al.   EUROPEAN RESPIRATORY JOURNAL

Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp- CFTR mutation: a phase 3, open-label extension study (PERSIST)

(2014) Edward F McKone et al.   Lancet Respiratory Medicine

Prognostic value of six minute walk test in cystic fibrosis adults

(2013) Clémence Martin et al.   RESPIRATORY MEDICINE

Cystic fibrosis transmembrane conductance regulator dysfunction and its treatment

(2012) Jeremy Hull   JOURNAL OF THE ROYAL SOCIETY OF MEDICINE

Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809

(2011) F. Van Goor et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA